Skip to main content

and
  1. Article

    Open Access

    Successful implementation of online educational lectures of the German Society for Radiation Oncology (DEGRO)

    Modern digital teaching formats have become increasingly important in recent years, in part due to the COVID-19 pandemic. In January 2021, an online-based webinar series was established by the German Society f...

    Marcel Büttner, Philip Melton, Rainer Fietkau in Strahlentherapie und Onkologie (2024)

  2. Article

    Open Access

    Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors

    This review article is intended to provide a perspective overview of potential strategies to overcome radiation resistance of tumors through the combined use of immune checkpoint and DNA repair inhibitors.

    Sandra Classen, Cordula Petersen, Kerstin Borgmann in Strahlentherapie und Onkologie (2023)

  3. No Access

    Article

    DNA as the main target in radiotherapy—a historical overview from first isolation to anti-tumour immune response

    DNA damage is one of the foremost mechanisms of irradiation at the biological level. After the first isolation of DNA by Friedrich Miescher in the 19th century, the structure of DNA was described by Watson and...

    Benjamin Frey, Kerstin Borgmann, Tina Jost in Strahlentherapie und Onkologie (2023)

  4. Article

    Open Access

    The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma

    Immune checkpoint inhibition is a therapeutic option in many cancer entities. In head and neck squamous cell carcinoma (HNSCC) targeting of the PD-1/PD-L1 (B7-H1) axis is approved in recurrent/metastatic disea...

    Mara Borgmann, Agnes Oetting, Felix Meyer in Journal of Cancer Research and Clinical On… (2023)

  5. Article

    Open Access

    Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L

    Head and neck squamous cell carcinoma (HNSCC) is often being diagnosed at an advanced stage, conferring a poor prognosis. The probability of local tumor control after radiotherapy depends on the eradication of...

    Jacqueline Nathansen, Vasyl Lukiyanchuk, Linda Hein, Maya-Isabel Stolte in Oncogene (2021)

  6. No Access

    Article

    A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types

    Triple-negative breast cancers (TNBC) are often resistant to treatment with ionizing radiation (IR). We sought to investigate whether pharmacologic inhibition of Chk1 kinase, which is commonly overexpressed in...

    Patrick H. Dinkelborg, Meng Wang, Liliana Gheorghiu in Breast Cancer Research and Treatment (2019)

  7. No Access

    Living Reference Work Entry In depth

    Basic Radiobiology

    In recent years, clinical radiotherapy has undergone considerable further development. This was primarily due to technological progress in adapting the radiation fields, the increasing adaptation of cytostatic...

    Ann Christin Parplys, Kerstin Borgmann in Radiation Oncology

  8. No Access

    Article

    Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck

    FGFR1 is a receptor tyrosine kinases involved in tumor growth signaling, survival, and differentiation in many solid cancer types. There is growing evidence that FGFR1 amplification might predict therapy respo...

    Till Sebastian Clauditz, Arne Böttcher in Journal of Cancer Research and Clinical On… (2018)

  9. No Access

    Chapter

    DNA Repair

    Cellular chromosomal DNA is the principal target through which ionising radiation exerts it diverse biological effects. This chapter summarises the relevant DNA damage signalling and repair pathways used by no...

    Kerstin Borgmann, Sabrina Köcher, Malte Kriegs in Molecular Radio-Oncology (2016)

  10. No Access

    Article

    Zur Interaktion von Strahlentherapie und Tamoxifen beim Mammakarzinom

    Tamoxifen (TAM) ist in der adjuvanten Therapie des Mammakarzinoms ebenso etabliert wie die Strahlentherapie; der optimale Zeitpunkt für den Beginn der Therapie mit TAM – simultan zur oder sequentiell nach Stra...

    PD Dr. Ulrike Hoeller, Kerstin Borgmann, Petra Feyer* in Strahlentherapie und Onkologie (2007)